Burkly Linda sold $19K of EDIT
Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) sold 7,814 shares of Editas Medicine, Inc. (EDIT) at $2.42 on 2026-11-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is small and unlikely to move the stock significantly.
Market read
Routine insider sale with limited trading relevance.
What to watch
Potential upcoming clinical data releases could offset any negative sentiment.
Background
Form 4 filing discloses insider transaction for Editas Medicine.
Ticker impact
EVP/Chief Scientific Officer sold 7,814 shares (~$19K) via 10b5-1 plan on 2026-11-11.
likely slight downward pressure as market prices the insider sell.
The sale is modest in size relative to holdings and market cap, so impact is limited.
Market effects
Minimal effect on biotech sector; routine insider transactions are common.
No regional impact.
Not globally relevant.
Counterpoint
The sale could be unrelated to company outlook; investors may ignore.
Key entities
- OfficerBurkly Linda
EVP, Chief Scientific Officer at Editas Medicine.


